Feb 25 (Reuters) - The health of Valeant Pharmaceuticals (N:VRX)
International Inc's VRX.TO Michael Pearson (L:PSON) is improving, the
company said on Thursday, but CNBC reported that there was
debate within the board over whether he was ready to return to
work.
Pearson, who joined Valeant VRX.N as chief executive in
2010, was hospitalized with severe pneumonia in late December.
The company named former Chief Financial Officer Howard
Schiller as interim CEO in January.
CNBC, citing a source, said Pearson was ready to return but
the board was debating whether he should.